Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by garygpon Jul 14, 2023 4:36pm
126 Views
Post# 35541964

RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - ProMIS Announces Completion of Continuance

RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - ProMIS Announces Completion of ContinuanceThis is all regualatory requirements and accounting basically.  When a corporation leaves one jurisdiction to enter another, all jurisdictions must be satisfied that the company is in good stead thus eliminating the threat of possible lawsuits and delays.  This is where good lawyers and accountants earn their keep.  As shareholders, this doesn't really affect us at all if the necessary processees are properly managed and carried out. The transition to the Nasdaq should be seamless.

Now as far as the Boston bunch are concerned, that's another story.  I believe a financing is close and this is why the stock is being obliterated, and by them,  Its simple.  Pound the stock into the basement, do a financing on the cheap, load up with cheap shares, dilute existing shareholders and limit their power.  If the Boston group don't take the financing, their friends and institutions will and all at currrent and future shareholders.  The long time holders here have been bent over the table and polished with a corn cob.  g.
<< Previous
Bullboard Posts
Next >>